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Abstract: Cigarette smoking causes lung inflammation and tissue damage. Lung fibroblasts play
a major role in tissue repair. Previous studies have reported smoking-associated changes in fibroblast
responses and methylation patterns. Our aim was to identify the effect of current smoking on miRNA
expression in primary lung fibroblasts. Small RNA sequencing was performed on lung fibroblasts
from nine current and six ex-smokers with normal lung function. MiR-335-5p and miR-335-3p were
significantly downregulated in lung fibroblasts from current compared to ex-smokers (false discovery
rate (FDR) <0.05). Differential miR-335-5p expression was validated with RT-qPCR (p-value = 0.01).
The results were validated in lung tissue from current and ex-smokers and in bronchial biopsies
from non-diseased smokers and never-smokers (p-value <0.05). The methylation pattern of the
miR-335 host gene, determined by methylation-specific qPCR, did not differ between current and
ex-smokers. To obtain insights into the genes regulated by miR-335-5p in fibroblasts, we overlapped all
proven miR-335-5p targets with our previously published miRNA targetome data in lung fibroblasts.
This revealed Rb1, CARF, and SGK3 as likely targets of miR-335-5p in lung fibroblasts. Our study
indicates that miR-335-5p downregulation due to current smoking may affect its function in lung
fibroblasts by targeting Rb1, CARF and SGK3.
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1. Introduction
Cigarette smoke consists of a complex mixture of thousands of toxic chemicals and over 1015
reactive oxygen species [1]. Oxidative stress caused by cigarette smoking can dysregulate cell function,
and induce the damage and death of the cellular constituents of the lungs [2]. Smoking is a major cause
of complex lung diseases such as chronic obstructive pulmonary disease. It is important to investigate
its effect in “normal” lung at the molecular level to gain a better understanding before investigating
its effect in complex lung diseases. Several studies have shown smoking-induced changes in gene
expression patterns in the lung. Epithelial cells are the first cells that encounter the inhaled smoke.
Consequently, aberrant gene expression signatures were reported in epithelial cells when comparing
current smokers with never-smokers [3,4]. Gene expression can be regulated by microRNAs (miRNAs).
These small non-coding RNAs influence their target gene and/or protein expressions by binding
based on sequence homology [5]. Marked changes in miRNA expression signatures have also been
reported in the bronchial airway epithelial cells, small airway epithelium, whole blood, and induced
sputum supernatant of current smokers compared to never-smokers [6–9]. The altered expression
signatures may be due to a direct effect of smoking, but can also be caused by indirect effects such
as smoking-induced aberrant DNA methylation patterns [10]. Most of the observed changes in gene
expression and methylation are (slowly) reversible, while some of the effects may be permanent [4,10].
A previous study showed that when smokers quit smoking for three months, 65% of the miRNAs that
were differentially expressed between current smokers and never-smokers return to the expression
level of never-smokers [7].
Lung fibroblasts are the main guardians of connective tissue homeostasis. Therefore,
lung fibroblasts, in close concert with other structural cells such as the epithelium, are considered
crucial cells for tissue repair and remodeling of the lungs. Cigarette smoke suppresses lung repair by
affecting multiple lung cells, as nicely reviewed by Rennard et al. [11]. Specific work in human lung
fibroblasts showed that the fibronectin and elastin production was inhibited upon cigarette smoke
extract (CSE) exposure [12,13]. In addition, lung fibroblasts were hampered in their proliferation,
contractile function, and migration toward fibronectin upon CSE exposure [12–14]. Furthermore,
human lung fibroblasts showed characteristics of senescence when treated with CSE [15].
To date, no information on differential miRNA expression in lung fibroblasts from donors with
different smoking statuses is available. We hypothesized that the miRNA expression profile in lung
fibroblasts is different in current smoking compared to ex-smoking donors, and that these changes in
miRNA expression may affect the function of the fibroblasts. The aim of our study was to identify
smoking status-related miRNA expression changes in lung fibroblasts and to assess miRNA-related
functions that may be affected by current smoking.
2. Results
2.1. Subject Characteristics
Clinical characteristics of lung fibroblast, lung tissue, and bronchial biopsy donors are
shown in Table 1. No significant difference was observed between current smokers, ex-smokers,
and never-smokers in age and forced expiratory volume in one second/forced vital capacity ratio
(FEV1/FVC). Moreover, the number of pack-years did not differ between current smokers and
ex-smokers. Furthermore, the characteristics of subjects from whom we have obtained lung fibroblasts
and those from whom we obtained lung tissue were not significantly different.
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Table 1. Patient characteristics of the donors of lung fibroblasts, lung tissue, and bronchial biopsy.
Characteristics
Lung Fibroblast Donors Lung Tissue Donors Bronchial Biopsy Donors
Ex-Smokers Current Smokers Never-Smokers Ex-Smokers Current Smokers Never-Smokers Current Smokers
N 9 6 14 33 20 42 40
Male/Female, n 6/3 1/5 6/8 21/12 7/13 23/19 23/17
Age, years 1 65.0 (55.0–68.0) 56.5 (48.5–69.0) 56.0 (48.8–73.8) 65.0 (54.0–71.5) 61.0 (51.3–67.8) 38.1 (21.6–57.8) 43.0 (23.4–52.4)
Pack-years, n 1 31.5 (17.9–43.1) (n = 6) 36.5 (27.8–52.0) (n = 6) NA 33.5 (20.0–46.3) (n = 26) 34.0 (20.3–50.8) (n = 16) NA 15.9 (3.9–30.3) (n = 40)
FEV1, % pred 1,2 96.9 (86.8–97.7) 92.4 3 102.0 (91.2–116.5) 90.9 (84.2–104.3) 94.2 (86.1–107.7) 101.2 (92.0–108.6) 97.7 (93.3–107.3)
FEV1/FVC, % 1,4 76.0 (71.4–79.9) 73.8 (73.1–79.2) 78.0 (72.8–83.0) 73.3 (70.0–78.9) 75.7 (72.6–79.2) 79.5 (75.0–85.4) 78.0 (73.9–83.0)
1 Median (interquartile range); 2 FEV1, % pred = percentage of forced expiratory volume in one second of the predicted normal value for an individual of the same sex, age, and height.
3 FEV1, % predicted was only available for three out of six current smokers who donated lung fibroblasts. Of these three donors, the FEV1 in liters is known. 4 FEV1/FVC, % = forced
expiratory volume in one second/forced vital capacity ratio expressed in percentage. NA = not applicable.
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2.2. Differential miRNA Expression in Lung Fibroblasts of Current and Ex-Smokers
The miRNA expression profiles of lung fibroblasts of nine ex-smoking and six current smoking
subjects were determined using small RNA sequencing. Total read counts and percentages of reads
mapping to miRBase Release 21 are shown in Table S1. The top 10 most abundant miRNAs in both
current smokers and ex-smokers covered 65% of all reads (Figure 1a). MiR-21-5p was the most
abundant miRNA in both subgroups.
Figure 1. MicroRNAs (miRNAs) in primary lung fibroblasts of ex-smokers and current smokers.
(a) Top 10 most abundant miRNAs in primary lung fibroblasts of ex-smokers and current smokers.
(b) Volcano plot of the 1339 miRNAs included in the analyses of the small RNA-sequencing data from
lung fibroblasts. The lowest horizontal line represents the nominal p-value cut-off of 0.05. The upper
horizontal line represents the false discovery rate (FDR) of 0.05. The two vertical lines represent the
negative (left) and positive (right) fold change of 1.5. Differentially expressed miRNAs are indicated
with a red dot. MiR-335-5p (FC = –1.8, FDR p-value = 0.0030) and miR-335-3p (FC = –1.6, FDR p-value
= 0.0285) were lower expressed in current smokers compared to ex-smokers.
A total of 18 miRNAs (five upregulated and 13 downregulated) differed between current smokers
and ex-smokers at a nominal p-value of <0.05 (Table S2). At a false discovery rate (FDR) cut-off
<0.05, miR-335-5p and miR-335-3p were significantly differentially expressed with lower expression
levels in current smokers compared to ex-smokers (fold change (FC) = –1.8, FDR p-value = 0.003
and FC = –1.6, FDR p-value = 0.0285, respectively; Figure 1b, Figure 2a, Figure S1a). Differential
expression of miR-335-5p (p-value = 0.01, Figure 2b), but not miR-335-3p (Figure S1b), was validated
using RT-qPCR in the same samples.
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Figure 2. Differentially expressed miR-335-5p in current smokers. (a) Standardized reads of miR-335-5p
in lung fibroblasts of ex-smokers and current smokers, derived from small RNA sequencing data,
as presented in Figure 1. ** FDR p-value = 0.0030. (b) Validation of miR-335-5p differential
expression in the same lung fibroblasts samples using RT-qPCR. The data are presented as relative
expression to RNU48 (2−∆Cp). One ex-smoker sample is missing due to a failure in experimental
procedures. ** p-value = 0.0100. (c) MiR-335-5p RT-qPCR analysis in lung tissues of ex-smokers and
current smokers. The data are presented as relative expression to RNU48 and RNU44 (2−∆Cp).
* p-value = 0.048. (d) MiR-335-5p standardized read counts from small RNA sequencing data of
bronchial biopsy samples. * p-value = 0.018.
2.3. Validation of miR-335-5p Differential Expression in Lung Tissue and Bronchial Biopsies
We validated the differential miR-335-5p expression in lung tissue from 20 current smokers
compared to 33 ex-smokers (p-value <0.05, Figure 2c). In lung tissue samples of never-smokers,
miR-335-5p expression was not significantly different from current smokers (Figure S2). In bronchial
biopsies of healthy subjects with normal lung function, we observed a significantly lower expression
of miR-335-5p in current smokers compared to never-smokers (p-value <0.05, FC = –1.2, Figure 2d).
To assess whether there is a direct smoke effect on miR-335-5p expression, we treated lung
fibroblasts from four ex-smokers with 2.5% and 5% CSE. CSE treatment resulted in slightly decreased
miR-335-5p levels in all (2.5% CSE) or three out of four fibroblast samples (5% CSE). This experiment
supported our findings (Figure 3) pointing toward a CSE-dependent decrease in miR-335-5p levels.
Figure 3. MiR-335-5p expression in cigarette smoke extract (CSE)-treated lung fibroblasts. The CSE
treatment started at passage 5 and lasted until the cells had reached a minimum of three cell divisions,
i.e., lung fibroblasts were treated with CSE for 21 days. MiR-335-5p expression in lung fibroblasts of
four ex-smokers (each individual is indicated with a symbol) treated with (a) 2.5% and (b) 5% CSE
(RT-qPCR). The data are presented as relative expression to RNU48 (2-∆Cp). * p-value <0.05 using
paired T-test.
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2.4. No Regional Hypermethylation in miR-335 Host Gene in Lung Tissue of Current Smokers
In a previous study of hepatocellular carcinoma, decreased miR-335-5p expression was shown to
be associated with the aberrant hypermethylation of a specific CpG island in an enhancer region of the
miR-335 host gene [16]. To examine whether the decreased miR-335-5p expression in current smokers
is due to hypermethylation, we did a methylation-specific qPCR (MSP) on the lung tissue samples used
for measuring the miR-335-5p expression in Figure 2c. The location of miR-335-5p, the analyzed CpG
island, and the primers used for the methylation specific qPCR are shown in Figure 4a. We found no
differences in the proportion of methylated DNA between current smokers and ex-smokers (Figure 4b).
The proportion of methylated DNA was also not correlated with miR-335-5p expression in lung tissue
(not shown). Furthermore, the methylation status did not show any obvious change after CSE treatment
in lung fibroblasts from ex-smokers (Figure S3a,b).
Figure 4. Methylation status in the CpG island of the enhancer region of miR-335-5p in lung tissue.
(a) Location of the primers for methylation-specific qPCR (MSP) and miR-335 (figure adapted from
Dohi et al. [16]). (b) Methylation status in specific CpG island was determined in lung tissue from
33 ex-smokers and 18 current smokers. The methylation status was determined as follows: 2ˆ(mean Cp
value methylated-specific primers—mean Cp value unmethylated-specific primers). A clear difference
was observed between the in vitro methylated and the unmethylated control DNA sample (not shown).
2.5. Predicted and Experimentally Proven Targets of miR-335-5p in the MiRNA Targetome of Lung Fibroblasts
We previously performed argonaute 2-immunoprecipitation (Ago2-IP) to identify the genes that
are actively regulated by miRNAs in primary lung fibroblasts from two control subjects. These genes
are collectively called the miRNA targetome [17]. To identify miR-335-5p target genes relevant in lung
fibroblasts, we first assessed the enrichment of predicted miR-335-5p target genes in our previously
published miRNA targetome of lung fibroblasts. In both controls, we observed 16 predicted miR-335-5p
target genes in the top 1500 Ago2-IP enriched probes; however, this was not a significant enrichment
compared to the proportion of miR-335-5p targets in all expressed genes (Table S3).
Next, we identified 40 experimentally proven target genes of miR-335-5p based on published
luciferase reporter assays [18–55] (Table S4). Of these genes, RB transcriptional corepressor 1 (Rb1) [18,19],
calcium responsive transcription factor (CARF) [20], and serum/glucocorticoid regulated kinase family member
3 (SGK3) [21] were present in the miRNA targetome of lung fibroblasts. In the RNA sequencing dataset
of bronchial biopsies [56], we observed an increase of SGK3 (FC = 1.1, p-value <0.05) in smokers
compared to never-smokers, whereas Rb1 and CARF were not significantly different.
3. Discussion
In this study, we found miR-335-5p levels to be lower in the parenchymal lung fibroblasts of
current smokers compared to those of ex-smokers, and this was validated in lung tissue. Moreover,
we also observed a lower miR-335-5p in bronchial biopsies from healthy current smokers compared to
never-smokers. A smoking-related decrease in miR-335-5p was supported by decreased miR-335-5p
levels upon the CSE treatment of fibroblasts. The lower expression level of this miRNA in the fibroblasts
and lung tissue of current smokers was not associated with hypermethylation of the previously reported
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CpG island. Next, we found that three previously published miR-335-5p target genes, i.e., Rb1, CARF,
and SGK3, were present in the miRNA targetome of lung fibroblasts.
The differential expression of miR-335-5p in lung fibroblasts suggests a potential role of this
miRNA in smoking-induced changes in fibroblast function. However, the exact role of miR-335-5p
in lung fibroblasts is as yet unknown. In bone-marrow derived human mesenchymal stem
cells, the overexpression of miR-335-5p had an inhibitory effect on cell proliferation, migration,
and differentiation [34]. This suggests that lower miR-335-5p levels as observed in current smokers
and upon CSE exposure in this study could result in enhanced proliferation, as well as in other
cell types, such as fibroblasts. However, other studies in lung fibroblasts showed the opposite, i.e.,
short and long-term CSE exposure reduced the proliferation and migration [13,14]. As the predicted
targets of miR-335-5p were not significantly enriched, we searched for the experimentally proven
targets. Three of these experimentally proven targets, i.e., Rb1, CARF, and SGK3, were enriched in
the Ago2-IP fraction in lung fibroblasts. The presence of these genes in the miRNA targetome shows
active targeting by miRNAs, and this might involve targeting by miR-335-5p in lung fibroblasts. As we
found a decreased expression of miR-335-5p in lung fibroblast from current smokers, we speculated
that these genes might be upregulated in current smokers. SGK3 is a serine/threonine protein kinase,
and to our knowledge, the function of this gene in lung fibroblasts is still unknown. Rb1 was the
most prominently IP-enriched target gene of miR-335-5p. This protein-coding gene can negatively
regulate the cell cycle by interacting with E2F Transcription Factor 1 (E2F1), which is required for the
activation of genes involved in the S phase of the cell cycle [57]. A previous study showed that nicotine
increased Rb1 expression in non-small cell lung cancer cell lines, and the knockdown of Rb1 inhibited
cell proliferation [58]. In contrast to this finding, cigarette smoking has been shown to inhibit the
proliferation of lung fibroblasts [13]. The second IP-enriched miR-335-5p target was CARF, which is
a transcriptional activator. CARF was shown to induce the transcription of brain-derived neurotrophic
factor (BDNF) exon III in rat neurons [59]. BDNF is also expressed in lung fibroblasts, and it was
previously reported that BDNF increased the cell proliferation of lung fibroblasts [60]. However, it is
unknown whether CARF also induces BDNF transcription in lung fibroblasts. Additional experiments
are required to investigate the role of miR-335-5p and the function of the identified target genes in
lung fibroblasts.
Furthermore, miR-335-5p has been reported to be involved in different cancer types, either as
a tumor suppressor or as an oncomiR [61]. The downregulation of miR-335-5p in different cancer
types was shown to be associated with aberrant DNA methylation [16,62,63]. As lung fibroblasts
had differential miRNA expression after isolation and the in vitro culturing of the fibroblasts, it is
conceivable that epigenetic changes are involved in the persistent change in miR-335-5p expression.
Pilot data using 5-aza-2’-deoxycytidine (not shown) suggested that miR-335-5p expression in fibroblasts
indeed may be regulated by DNA methylation. In our study, we focused on a specific CpG island
in the miR-335 host gene enhancer region that was reported by Dohi et al. [16]. However, we did
not find differences in the methylation status in lung tissue from current smokers and ex-smokers.
Moreover, the methylation status of this specific region was also unchanged in lung fibroblasts from
ex-smokers after CSE treatment. Thus, our findings suggest that the smoking-related downregulation
of miR-335-5p in lung fibroblasts is not due to aberrant DNA methylation at this specific region.
However, we cannot exclude that aberrant DNA methylation is present at other regions, which also
may affect miR-335-5p expression. In addition to aberrant DNA methylation, cigarette smoke-induced
histone modification in the lung has been reported [64], and thus is worthwhile to investigate.
We showed lower miR-335-5p levels in fibroblasts and lung tissue from current smokers compared
to ex-smokers and in bronchial biopsies, as well as compared to never-smokers. However, in lung
tissue, we did not observe a difference between current smokers and never-smokers. This could be due
to lack of power, as the never-smoking group only consisted of 14 subjects.
In conclusion, we showed a lower miR-335-5p expression in lung fibroblasts and tissues from
current smokers compared to ex-smokers, and in bronchial biopsies from current smokers compared
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to never-smokers, without a change in the regional methylation pattern of its host gene. The decreased
expression of miR-335-5p in lung fibroblasts from current smokers may have an effect on the cell
function via targeting Rb1, CARF, and SGK3.
4. Materials and Methods
4.1. Subjects
Small RNA sequencing was performed on human parenchymal lung fibroblasts isolated from the
tissue samples of nine ex-smokers and six current smokers with normal lung function who underwent
lung tumour resection surgery. Left-over, macroscopically normal lung tissue samples located far away
from the tumor were used for the isolation of lung fibroblasts [65,66].
As validation cohorts, we analyzed lung tissue samples of 33 ex-smoking and 20 current smoking
individuals with normal lung function by RT-qPCR. These lung tissue samples were also derived from
ex-smokers and current smokers with normal lung function who underwent lung tumour resection
surgery. In addition, we analyzed data from the bronchial biopsies of 42 never-smoking and of
40 currently smoking healthy individuals with normal lung function and no respiratory symptoms
(Clinical Trials Identifier = NCT00848406 [67]).
This study was performed in accordance with the national ethical and professional guidelines
on the use of human body material (“Code of conduct; Dutch federation of biomedical
scientific societies”; https://www.federa.org/codes-conduct) and the Research Code of the University
Medical Center Groningen (https://www.umcg.nl/SiteCollectionDocuments/English/Researchcode/
umcg- research-code-2018-en.pdf). At the time of the experiments, the use of left-over lung tissue to
isolate fibroblasts or to replicate the results did not fall within the scope of medical research involving
human subjects in the Netherlands. Therefore, an ethics waiver was provided by the Medical Ethical
Committee of the University Medical Center Groningen (METc UMCG). All samples and clinical
information were de-identified before the start of the experimental procedures in this study.
4.2. Isolation, Cell Culture, and CSE Treatment of Primary Lung Fibroblasts
Primary lung fibroblasts were isolated and grown in complete Ham’s F12 medium supplemented
with 10% (v/v) fetal calf serum (FCS), 100 U/mL penicillin/streptomycin, and 200 mM L-glutamine (all
from Lonza, Breda, The Netherlands) and stored in liquid nitrogen until further use as previously
described [17,68]. Fibroblast cultures were restored, cultured until passage 5, grown to around 90–100%
confluence in complete Ham’s F12 culture medium, and then serum-starved (0.5% (v/v) FCS) for
24 hours before harvesting of the cells for RNA isolation.
Fibroblasts of four ex-smoking individuals were treated with 0%, 2.5%, and 5% CSE for 21 days to
determine long-term smoke-exposure effects. Two 3R4F research-reference filterless cigarettes (Tobacco
Research Institute, University of Kentucky, 12/2006) were bubbled into 25 ml complete Ham’s F12
medium supplemented with 10% (v/v) FCS, 100 U/mL penicillin/streptomycin, and 200 mM l-glutamine
(all from Lonza) using a peristaltic pump. This was considered as 100% CSE, which was then diluted
to 2.5% and 5% CSE in complete medium. The CSE treatment started at passage 5, and lasted until the
cells had reached a minimum of three cell divisions. During cell culturing, half of the medium with
and without CSE was replaced with fresh medium whenever there was an obvious change in color.
The fibroblasts were harvested at passage 7 for RNA and DNA isolation.
4.3. RNA and DNA Isolation
Total RNA was isolated from primary lung fibroblasts and lung tissue samples using TRIzol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Genomic DNA was isolated
using salt–chloroform extraction and isopropanol precipitation using standard procedures. The RNA
and DNA concentrations were measured with a NanoDrop 1000 Spectrophotometer (Thermo Scientific,
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Wilmington, DE, USA). For small RNA sequencing, the RNA quantity and quality were determined
using the LabChip GX (Perkin Elmer, Waltham, MA, USA).
4.4. Small RNA Sequencing
Total RNA (approximately 1 µg) was used to generate libraries with the NEXTflex Small RNA-seq
kit V3 (Bioo Scientific, Uden, The Netherlands). Sequencing was performed on the NextSeq 500
sequencing system (Illumina, San Diego, CA, USA) according to the protocol of the manufacturer.
TrimGAlore 0.3.7 was used to trim the adapter sequences of the raw reads. Subsequently, the reads
were allocated to the known human miRNAs allowing one mismatch using the miRDeep2 V2.0.0.8
software [69] and miRBase Release 21 (http://www.mirbase.org/). The reads of miRNAs with the
same mature sequence were summed up. Using the default filtering setting of the DESeq2 package
in R, miRNAs not expressed in all samples were removed. This resulted in 1339 miRNAs for further
analyses. The small RNA sequencing dataset generated for this manuscript is available for collaboration
upon request.
4.5. RT-qPCR
To validate the differential miRNA expression, RT-qPCR was performed as described previously [17].
First, 10 ng of total RNA was reverse-transcribed using a multiplex approach with TaqMan primers
(reference gene: RNU48 (Assay ID: 001006) or RNU44 (Assay ID: 001094), ssc-miR-335-5p (Assay ID:
244560_mat) and hsa-miR-335* (hsa-miR-335-3p, Assay ID:002185); Applied Biosystems, Carlsbad, CA,
USA) [70]. Subsequently, qPCR was done using TaqMan microRNA assays (Applied Biosystems) and
a LightCycler®480 Probes Master (Roche Diagnostics GmbH, Mannheim, Germany).
The reactions were run in triplicate on the LightCycler®480 Real-Time PCR system (Roche
Diagnostics GmbH). The LightCycler®480 software release 1.5.0 (Roche Diagnostics GmbH) was used
to analyze the data. The relative miRNA expression levels were calculated using the formula 2−∆Cp.
4.6. Bisulfite Treatment and Methylation-Specific qPCR
DNA from primary lung fibroblasts and lung tissue samples was treated with bisulfite using
the EZ DNA Methylation-Gold™ Kit (Zymo Research, Irvine, CA, USA) according to the protocol of
the manufacturer. The DNA of leukocytes in vitro methylated by SssI methyltransferase was used as
a positive control, and untreated DNA was used as a negative control [71]. MSP for the miR-335 host gene
was done on 10 ng of bisulfite-treated DNA using SYBR green PCR master mix (Applied Biosystems)
and previously published methylated-specific primers (forward 5’-TTGTAATAGGTGGCGTTGAC-3’
and reverse 5’-ACTCGAAACTAAAACGTCGC-3’) and unmethylated-specific primers (forward
5’-TTTTTGTAATAGGTGGTGTTGAT-3’ and reverse 5’-ACTCAAAACTAAAACATCACCAA-3’) [16].
For each sample, qPCR with the methylated-specific and unmethylated-specific primers (annealing
temperature 58 ◦C for 1.20 min) were run in triplicate on the same plate. The methylation status
was determined as follows: 2ˆ (mean Cp value methylated-specific primers—mean Cp value
unmethylated-specific primers).
4.7. Identification of miR-335-5p Targets Relevant for Lung Fibroblasts
We re-analyzed our previously published Ago2-IP data of primary lung fibroblasts from two
control subjects to identify miR-335-5p target genes that are Ago2-IP-enriched, and thus targeted by
miRNAs in lung fibroblasts [17]. This was done for a list of predicted targets of miR-335-5p identified
using TargetScan version 7.2 [72] and for a list of experimentally proven, direct targets of miR-335-5p
that was generated based on validation with luciferase reporter assays.
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4.8. Statistical Analyses
To compare the subject characteristics between and within the study groups, Mann–Whitney
U-test was used in IBM SPSS Statistics 20 software. Differential expression analysis of the small RNA
sequencing data comparing miRNA expression in the lung fibroblasts of ex-smokers and current
smokers, and in bronchial biopsies of never-smokers and current smokers, was performed using
the Bioconductor-DESeq2 package (version 1.14.1) in R Project software (version 3.3.2). The data
were adjusted for age, gender, and library preparation batch. A Benjamini–Hochberg FDR <0.05 was
considered statistically significant.
For RT-qPCR data, significant differences for miR-335-5p levels in lung fibroblasts and lung tissues
between current smokers and ex-smokers were tested using the one-tailed Mann–Whitney U-test.
A paired T-test was used to test for miR-335-5p expression changes in CSE-treated lung fibroblasts.
A chi-square test was performed on the percentage of predicted targets in the top 1500 enriched probes
compared to the percentage of predicted targets in all expressed genes to assess the enrichment of
predicted target genes in the Ago2-IP. A p-value below 0.05 was considered statistically significant.
Our previously published RNA-seq data in bronchial biopsies [56] were used to validate the
proposed target genes. Differential expression analysis comparing current smokers with never-smokers
was performed using the Bioconductor-DESeq2 package (version 1.14.1) in R Project software (version
3.3.2). The data were adjusted for age, gender, and batch.
Supplementary Materials: The Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
5176/s1.
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